JPWO2019178462A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019178462A5 JPWO2019178462A5 JP2020542898A JP2020542898A JPWO2019178462A5 JP WO2019178462 A5 JPWO2019178462 A5 JP WO2019178462A5 JP 2020542898 A JP2020542898 A JP 2020542898A JP 2020542898 A JP2020542898 A JP 2020542898A JP WO2019178462 A5 JPWO2019178462 A5 JP WO2019178462A5
- Authority
- JP
- Japan
- Prior art keywords
- leu
- ala
- trp
- exist
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 31
- 229920001184 polypeptide Polymers 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000000539 amino acid group Chemical group 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 13
- 229930195729 fatty acid Natural products 0.000 claims description 13
- 239000000194 fatty acid Substances 0.000 claims description 13
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 7
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 7
- 239000000199 parathyroid hormone Substances 0.000 claims description 7
- 229960001319 parathyroid hormone Drugs 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims description 2
- 208000013403 hyperactivity Diseases 0.000 claims description 2
- 229940125425 inverse agonist Drugs 0.000 claims description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644316P | 2018-03-16 | 2018-03-16 | |
| US62/644,316 | 2018-03-16 | ||
| PCT/US2019/022439 WO2019178462A1 (en) | 2018-03-16 | 2019-03-15 | Parathyroid hormone polypeptide conjugates and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516222A JP2021516222A (ja) | 2021-07-01 |
| JPWO2019178462A5 true JPWO2019178462A5 (https=) | 2022-03-23 |
| JP2021516222A5 JP2021516222A5 (https=) | 2022-03-23 |
Family
ID=67908395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542898A Pending JP2021516222A (ja) | 2018-03-16 | 2019-03-15 | 副甲状腺ホルモンポリペプチドコンジュゲートおよびその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11975050B2 (https=) |
| EP (1) | EP3765061A4 (https=) |
| JP (1) | JP2021516222A (https=) |
| WO (1) | WO2019178462A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022014907A (es) * | 2020-05-26 | 2023-01-04 | Univ Indiana Res & Tech Corp | Analogos de la hormona paratiroidea para el tratamiento del hipoparatiroidismo. |
| EP4593867A2 (en) | 2022-09-30 | 2025-08-06 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
| WO2025250793A1 (en) * | 2024-05-29 | 2025-12-04 | The General Hospital Corporation | Parathyroid hormone polypeptide conjugates and methods of their use |
| WO2026067798A1 (zh) * | 2024-09-30 | 2026-04-02 | 长春金赛药业有限责任公司 | Pth复合物及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5261686A (en) | 1992-04-06 | 1993-11-16 | Buckler Clive E | Semi-recumbent |
| US7132260B2 (en) | 1991-04-05 | 2006-11-07 | The General Hospital Corporation | DNA encoding parathyroid hormone receptor |
| ATE287898T1 (de) | 1991-04-05 | 2005-02-15 | Gen Hospital Corp | Parathyroid-hormon-rezeptor und seine kodierende dna |
| US7150974B1 (en) | 1991-04-05 | 2006-12-19 | The General Hospital Corporation | Parathyroid hormone receptor binding method |
| DE69734157T2 (de) | 1996-07-31 | 2006-07-13 | The General Hospital Corp., Boston | Parathyroidhormon-verwandthe peptidanaloge |
| US6183974B1 (en) | 1997-07-31 | 2001-02-06 | The General Hospital Corporation | Screening assays for G protein coupled receptor agonists and antagonists |
| AU1447600A (en) | 1998-10-22 | 2000-05-08 | Thomas J. Gardella | Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp) |
| DE69942035D1 (de) | 1998-11-25 | 2010-04-01 | Gen Hospital Corp | Menschliches parathyroidhormon, modifikationen, herstellung und verwendung |
| US6537965B1 (en) | 1998-11-25 | 2003-03-25 | The General Hospital Corporation | Amino-terminal modified parathyroid hormone (PTH) analogs |
| AU4217299A (en) | 1998-11-30 | 2000-06-19 | General Hospital Corporation, The | Pth1r and pth3r receptors, methods and uses thereof |
| EP1141237B1 (en) | 1998-12-31 | 2005-11-02 | The General Hospital Corporation | Pth receptor and screening assay utilizing the same |
| US7057012B1 (en) | 1998-12-31 | 2006-06-06 | The General Hospital Corporation | PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| US7022815B1 (en) | 1999-09-29 | 2006-04-04 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (PTH) |
| AU7734800A (en) | 1999-09-29 | 2001-04-30 | General Hospital Corporation, The | Polypeptide derivatives of parathyroid hormone (pth) |
| CA2454275C (en) | 2001-07-23 | 2012-10-23 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
| US7087229B2 (en) * | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| AU2003217243A1 (en) | 2003-01-24 | 2004-08-23 | Thomas J. Gardella | Conformationally constrained parathyroid hormone (pth) analogs with lactam bridges |
| US7795220B2 (en) | 2003-03-19 | 2010-09-14 | The General Hospital Corporation | Conformationally constrained parathyroid hormones with alpha-helix stabilizers |
| WO2005009358A2 (en) | 2003-07-17 | 2005-02-03 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
| KR101241862B1 (ko) * | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| US9387235B2 (en) * | 2004-06-14 | 2016-07-12 | Basf Beauty Care Solutions France S.A.S. | Cosmetic preparations containing PTH fragments |
| EP2054077A4 (en) | 2006-08-04 | 2010-10-13 | Gen Hospital Corp | POLYPEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) |
| AU2008282805B2 (en) | 2007-08-01 | 2014-05-01 | Chugai Pharmaceutical Co., Ltd. | Screening methods using G-protein coupled receptors and related compositions |
| US20110294738A1 (en) * | 2008-11-04 | 2011-12-01 | Yong Ren | Pthr1 receptor compounds |
| EP2411038B1 (en) * | 2009-03-27 | 2016-12-28 | Van Andel Research Institute | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
| WO2011143406A2 (en) | 2010-05-13 | 2011-11-17 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
| MX2018009938A (es) * | 2016-03-01 | 2019-03-14 | Ascendis Pharma Bone Diseases As | Profarmacos de hormona paratiroidea (pth). |
| WO2017173372A1 (en) * | 2016-04-01 | 2017-10-05 | The General Hospital Corporation | Parathyroid hormone receptor 1 antagonist and inverse agonist polypeptides and methods of their use |
| EP3518961B1 (en) * | 2016-09-29 | 2023-02-22 | Ascendis Pharma Bone Diseases A/S | Pth compounds with low peak-to-trough ratios |
| KR101964376B1 (ko) * | 2017-09-29 | 2019-04-01 | 주식회사 나이벡 | 부갑상선호르몬(parathyroid hormone, PTH)에 골조직 선택성 펩타이드가 결합되어 있는 융합 펩타이드를 포함하는 약학 조성물 및 생체재료 |
-
2019
- 2019-03-15 WO PCT/US2019/022439 patent/WO2019178462A1/en not_active Ceased
- 2019-03-15 EP EP19767380.9A patent/EP3765061A4/en active Pending
- 2019-03-15 JP JP2020542898A patent/JP2021516222A/ja active Pending
- 2019-03-15 US US16/980,944 patent/US11975050B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rand-Weaver et al. | Isolation and characterization of somatolactin, a new protein related to growth hormone and prolactin from Atlantic cod (Gadus morhua) pituitary glands | |
| JP3164463B2 (ja) | ペプチド類 | |
| RU2485135C2 (ru) | Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты) | |
| JP2021516222A5 (https=) | ||
| AU2020363214B2 (en) | Active polypeptide compound | |
| CA2302255A1 (en) | Fracture healing using pthrp analogs | |
| IE921121A1 (en) | GRF-Analogs II | |
| IL147652A (en) | Peptide- type compound having an activity of increasing an intracellular calcium ion concentration | |
| RU2000109305A (ru) | ЗАЖИВЛЕНИЕ ПЕРЕЛОМОВ С ПОМОЩЬЮ АНАЛОГОВ ПЕПТИДА, ПОДОБНОГО ПАРАТИРЕОИДНОМУ ГОРМОНУ (РТНrР) | |
| JPH11505807A (ja) | 生物学的活性が増加したキメラ脂肪体プロｇｒｆ類似体 | |
| IL98638A (en) | Analogs of the factor that releases human growth hormone, their preparation and pharmaceutical preparations that contain them | |
| JP2004277402A (ja) | 胃切除術を受けた個体の低体重及び低体脂肪量を治療するためのグレリンの使用 | |
| CN101983068B (zh) | N末端和c末端取代的人gh-rh拮抗类似物 | |
| EP2794647B1 (en) | Novel gh-rh analogs with potent agonistic effects | |
| AU2004265280A1 (en) | Antagonistic analogs of GH-RH (2003) | |
| JPWO2019178462A5 (https=) | ||
| AU2003236080B2 (en) | A method for producing a modified peptide | |
| JPH0725799B2 (ja) | 高カルシウム体液性因子拮抗薬 | |
| CN109153712B (zh) | Peg化生物活性肽及其用途 | |
| JP6113144B2 (ja) | 成長ホルモン放出因子（ｇｒｆ）類似体およびその使用 | |
| HU211346A9 (en) | Stabilized potent grf analogs | |
| CN113527506A (zh) | 融合蛋白及其应用 | |
| EP0405763A1 (en) | GRF peptides | |
| US20030027753A1 (en) | Bone stimulating factor | |
| JPWO2023108126A5 (https=) |